Birchview Capital’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Birchview Capital’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$41K	Buy	17,503 +503	+3%	+$1.3K	0.02%	71
2025 Q4	$22.9K	Hold	17,000	–	–	0.01%	68
2025 Q3	$25.7K	Hold	17,000	–	–	0.02%	69
2025 Q2	$19.7K	Hold	17,000	–	–	0.02%	70
2025 Q1	$27K	Hold	17,000	–	–	0.02%	68
2024 Q4	$51.5K	Buy	17,000 +1,000	+6%	+$3.28K	0.04%	66
2024 Q3	$58.9K	Hold	16,000	–	–	0.05%	58
2024 Q2	$65.4K	Hold	16,000	–	–	0.06%	58
2024 Q1	$252K	Hold	16,000	–	–	0.21%	49
2023 Q4	$242K	Buy	+16,000	New	+$233K	0.19%	47
2022 Q3	–	Sell	-8,000	Closed	-$225K	–	61
2022 Q2	$225K	Hold	8,000	–	–	0.16%	49
2022 Q1	$369K	Hold	8,000	–	–	0.27%	45
2021 Q4	$672K	Hold	8,000	–	–	0.43%	38
2021 Q3	$533K	Hold	8,000	–	–	0.36%	39
2021 Q2	$426K	Buy	+8,000	New	+$428K	0.25%	46

Other funds holding ZNTL

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $273M AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Birchview Capital's ZNTL Position: Q1 2026 in Review

Birchview Capital increased its Zentalis Pharmaceuticals (ZNTL) stake by 3% in Q1 2026, buying an estimated $1.3K and bringing the position to 17,503 shares worth $41K. The position accounts for 0.02% of the portfolio, ranked #71.

Birchview Capital first reported a position in ZNTL in Q2 2021 and has held it in 15 quarters since. The position peaked at $672K in Q4 2021. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

Birchview Capital held 17,503 shares of Zentalis Pharmaceuticals worth $41K as of Q1 2026.
Birchview Capital bought 503 Zentalis Pharmaceuticals shares in Q1 2026, an estimated $1.3K.
Zentalis Pharmaceuticals made up 0.02% of Birchview Capital's portfolio in Q1 2026, its #71 holding.
Birchview Capital first reported a position in Zentalis Pharmaceuticals in Q2 2021 and has held it in 15 quarters since.
Birchview Capital's Zentalis Pharmaceuticals position peaked at $672K in Q4 2021.
102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on Birchview Capital's 13F filing for Q1 2026, filed 15 May 2026.